Mice Without VIP Had Less Severe Colitis — The Opposite of What Researchers Expected
Mice genetically lacking vasoactive intestinal peptide (VIP) unexpectedly developed milder colitis with lower inflammatory markers, challenging the prevailing view that VIP is purely protective in gut inflammation.
Quick Facts
What This Study Found
When TNBS-induced colitis (a model for Crohn's disease) was triggered in VIP knockout mice, they showed a milder clinical profile compared to wild-type mice. Serum levels of TNF-α and IL-6 were lower in VIP-deficient mice. However, colon histopathological scores and local cytokine levels did not differ between the groups, indicating that VIP's absence selectively disrupted certain but not all immunological compartments.
Interestingly, splenocytes from TNBS-treated VIP knockout mice showed enhanced proliferative responses to T cell stimulation (anti-CD3/CD28), suggesting that while some immune functions were dampened, T cell reactivity was actually increased. This pattern — reduced clinical disease but enhanced T cell responses — mirrors findings in VIP knockout mice with endotoxemia and autoimmune encephalomyelitis.
Key Numbers
Lower TNF-α and IL-6 in VIP KO mice; enhanced splenocyte proliferative response to anti-CD3/CD28 in VIP KO mice
How They Did This
Researchers administered TNBS (a chemical that induces colitis resembling Crohn's disease) intracolonically to both VIP knockout mice and wild-type controls. They tracked weight loss and disease severity over time, analyzed colon tissue for damage and immune cell infiltration (myeloperoxidase activity), measured TNF-α and IL-6 in both colon tissue and blood, and tested how well spleen immune cells from treated mice responded to T cell stimulation in the lab.
Why This Research Matters
VIP has been investigated as a potential therapy for inflammatory bowel disease based on decades of research showing it reduces inflammation when injected. This study complicates that narrative by showing that the body's own VIP isn't simply protective — its chronic absence actually makes some aspects of colitis less severe. This is important for anyone developing VIP-based therapies, because the relationship between endogenous VIP signaling and gut inflammation is not the straightforward anti-inflammatory story that was assumed.
The Bigger Picture
This study is part of a growing body of evidence showing that neuropeptides like VIP have dual roles in immunity — sometimes protective, sometimes harmful, depending on the context. The finding aligns with similar paradoxical results in VIP knockout mice with endotoxemia and autoimmune encephalomyelitis, suggesting that chronic VIP deficiency causes broad immune reprogramming rather than simply removing an anti-inflammatory brake. This has major implications for the development of VIP-based therapeutics for IBD.
What This Study Doesn't Tell Us
The study used constitutive VIP knockout mice, meaning VIP was absent from birth. This chronic absence may have caused compensatory changes in the immune system that wouldn't occur with acute VIP manipulation. The TNBS colitis model is a chemical model that doesn't fully replicate human Crohn's disease. Not all parameters showed differences — histopathological scores were similar between groups — suggesting the milder phenotype was selective rather than comprehensive.
Questions This Raises
- ?Would acutely blocking VIP in adult mice show the same paradoxical reduction in colitis, or is this effect dependent on lifelong absence?
- ?How does VIP simultaneously promote and suppress different aspects of the inflammatory response in the gut?
- ?Should VIP-based IBD therapies be reconsidered given the complex dual role of endogenous VIP in intestinal inflammation?
Trust & Context
- Key Stat:
- Milder colitis without VIP VIP knockout mice showed reduced clinical severity and lower inflammatory cytokines — the opposite of what was predicted for a peptide considered anti-inflammatory.
- Evidence Grade:
- Rated preliminary: well-controlled knockout mouse study with systematic multi-parameter assessment, but the results are paradoxical and may reflect compensatory changes from lifelong VIP absence rather than the direct role of VIP in colitis.
- Study Age:
- Published in 2015 in Neuroimmunomodulation. The findings remain relevant to ongoing debates about VIP's therapeutic potential in IBD and the broader complexity of neuropeptide-immune interactions.
- Original Title:
- Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.
- Published In:
- Neuroimmunomodulation, 22(3), 203-12 (2015)
- Database ID:
- RPEP-02571
Evidence Hierarchy
Tests effects in animals (usually mice or rats), not humans.
What do these levels mean? →Frequently Asked Questions
If VIP is anti-inflammatory, why did mice without it have less inflammation?
That's the central paradox. While injecting VIP reduces inflammation in colitis models, mice born without VIP appear to develop compensatory changes in their immune system. The result is that some inflammatory pathways are dampened while T cell responses are actually enhanced — suggesting VIP plays a more complex role than simply being an 'off switch' for inflammation.
Does this mean VIP therapy for IBD won't work?
Not necessarily, but it complicates the picture. Acutely giving VIP to treat active inflammation may still help, but this study shows that the body's ongoing VIP signaling has both pro- and anti-inflammatory effects. Future therapies may need to target specific VIP pathways rather than just adding more VIP.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-02571APA
Abad, Catalina; Cheung-Lau, Gardenia; Coûté-Monvoisin, Anne-Claire; Waschek, James A. (2015). Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.. Neuroimmunomodulation, 22(3), 203-12. https://doi.org/10.1159/000364912
MLA
Abad, Catalina, et al. "Vasoactive intestinal peptide-deficient mice exhibit reduced pathology in trinitrobenzene sulfonic acid-induced colitis.." Neuroimmunomodulation, 2015. https://doi.org/10.1159/000364912
RethinkPeptides
RethinkPeptides Research Database. "Vasoactive intestinal peptide-deficient mice exhibit reduced..." RPEP-02571. Retrieved from https://rethinkpeptides.com/research/abad-2015-vasoactive-intestinal-peptidedeficient-mice
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.